SOUTH SAN FRANCISCO, CA -- (MARKET WIRE) -- February 20, 2007 -- Novacea, Inc. (NASDAQ: NOVC) today announced the Journal of Clinical Oncology (JCO) has published findings from the large Phase 2 trial of its lead investigational cancer therapy, DN-101 (Asentar™), entitled ASCENT (AIPC Study of Calcitriol Enhancing Taxotere). ASCENT was a double-blinded, placebo-controlled, randomized, multi-site trial of DN-101 plus docetaxel (Taxotere) vs. placebo plus docetaxel in androgen-independent prostate cancer (AIPC). The JCO publication reports that DN-101 may help advanced prostate cancer patients live longer while experiencing fewer chemotherapy-associated side effects and complications of their cancer. Asentar is an investigational new drug that is an oral, intermittent, high-dose of calcitriol, the most potent natural ligand or activator of the calcitriol receptor (also known as the vitamin D receptor).
